Teleflex Incorporated (TFX) Stock Analysis 2026

HealthcareMedical Instruments & Supplies
$141.39
as of 2026-10-29
+2.8% (52-week)50D MA $130.88  |  200D MA $124.37

BriMind AI Score

Proprietary
28
Weak
Price CAGR
-1.4%
1Y Return
+3.3%
Analyst Upside
+13.0%
Rev Growth
28.9%

Score based on historical price CAGR, revenue growth, analyst upside, and valuation factors. Updated daily.

BriMind 1-Year Price Target

$148.70+5.2% potential
Bear Case
$118.14
Bull Case
$186.56
Model Confidence90%

An even blend of the BriMind AI model's DCF and momentum target ($143.40) and Wall Street's consensus target ($154.00).

AI scores and price targets are for informational and educational purposes only. They do not constitute financial advice or a recommendation to buy or sell any security. Past performance is not indicative of future results. Always conduct your own research before making investment decisions. Full Disclaimer →

TFX Revenue & Profitability Breakdown

This chart shows how TFX's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Revenue
$2.25B
Cost of Revenue
-$1.01B
Gross Profit
$1.24B55.1% margin
Operating Expenses
-$1.02B
Operating Income
$226.8M10.1% margin
Tax & Other
-$1.26B
Net Income
-$-1.03B-45.8% margin
Gross Margin
55.1%
Operating Margin
10.1%
Net Margin
-45.8%
EBITDA Margin
28.0%

Key Financial Metrics

Teleflex Incorporated trades at a trailing P/E of 2734.20x, generates $179.5M in free cash flow, runs a debt/equity ratio of 101.10, and converts shareholder equity into profit at a -0.7% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Market Cap
$5.77B
Enterprise Value
$7.16B
P/E (Trailing)
2734.20
P/E (Forward)
12.45
PEG Ratio
0.16
EV / EBITDA
8.50
Price / Sales
1.80
Price / Book
1.99
Revenue
$2.25B
Revenue Growth
28.9%
Earnings Growth
-17.3%
EBITDA
$842.4M
EPS (Trailing)
$-8.48
EPS (Forward)
$10.94
Gross Margin
55.1%
Operating Margin
10.1%
Net Margin
-45.8%
Return on Equity
-0.7%
Return on Assets
1.7%
Free Cash Flow
$179.5M
Total Cash
$293.4M
Total Debt
$2.03B
Debt / Equity
101.10
Current Ratio
2.60
Quick Ratio
0.96
Beta
0.83
Dividend Yield
1.0%
Payout Ratio
103.8%
Insider Ownership
0.6%
Inst. Ownership
114.9%
Short % Float
15.0%
Book Value / Share
$68.55

Wall Street Analyst Consensus

10 analysts covering Teleflex Incorporated currently lean toward a Underperform rating, with a mean 12-month price target of $154.00 (+8.9% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

Consensus RatingUnderperform(10 analysts)
SellStrong Buy
Low Target$135.00-4.5%
Mean Target$154.00+8.9% upside
High Target$200.00+41.5%

Intrinsic Value Estimates for TFX

We use 2 valuation models to estimate TFX's intrinsic value. Intrinsic value is what a stock is truly worth based on the company's fundamentals, independent of what the market prices it at today. If multiple models agree the stock is undervalued, that convergence is a stronger signal.

DCF Model (10yr)
$85.32
-39.7% vs current
Discounts 10 years of projected free cash flow back to today's dollars (5% growth, 10% discount rate). Best for companies generating consistent cash.
P/E Based (15× forward)
$164.16
+16.1% vs current
Multiplies next year's estimated earnings per share by 15×. More forward-looking; useful for high-growth companies where current earnings understate potential.
Fair Value Range
$85.32 – $164.16
Average Estimate
$124.74
Potential Downside
-11.8%

Intrinsic value estimates use simplified models (Graham, DCF, P/E) and conservative assumptions. They should be used as one input among many — not as sole buy/sell guidance. For advanced analysis, see the full platform.

Technical Price Signals

TFX is currently in a golden cross pattern, trading above its 50-day average of $130.88 and above its 200-day average of $124.37. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

Current Price
$141.39
50-Day MA
$130.88
▲ Price above
200-Day MA
$124.37
▲ Price above
Golden Cross Pattern
Price above both MAs — bullish signal

Further Reading

Research and guides that put TFX’s numbers in context — how to read the filings behind them, and the frameworks we use to score them.

Risk ManagementBest ETFs for a Recession-Proof Portfolio in 2026FundamentalsHow to Read a 10-K Annual Report: Complete Investor GuideFundamentals10 Stock Analysis Tools Every Investor Should Know AboutFundamentalsFactor Investing Guide 2026: Value, Momentum, Quality & Low Volatility — Which Factors Work?

More Healthcare Stock Analysis

In-depth reports on companies operating alongside TFX — business models, bull and bear cases, and the metrics that matter.

ALGNAlign Technology, Inc.Medical Instruments & SuppliesISRGIntuitive Surgical, Inc.Medical Instruments & SuppliesNVSTEnvista Holdings CorporationMedical Instruments & SuppliesSYKStryker CorporationMedical DevicesMOHMolina Healthcare, Inc.Healthcare PlansSRPTSarepta Therapeutics, Inc.BiotechnologyPFEPfizer Inc.Drug Manufacturers - GeneralLLYEli Lilly and CompanyDrug Manufacturers - General

Unlock the Full TFX Analysis

Interactive price charts, real-time AI signals, advanced DCF models, portfolio tracking, earnings analysis, and side-by-side peer comparisons. Start your 14-day free trial — no credit card required.

Start Free TrialBrowse All Stocks
Data sources: Financial metrics and market data sourced from company SEC filings, earnings releases, and investor relations disclosures. Price data, analyst consensus targets, and fundamental financials provided by financial market data providers. ETF data sourced from official fund prospectuses and index provider publications. AI scores and price targets are proprietary estimates — see our Methodology and Disclaimer for details.
← Back to Home · Browse All Stock Analysis